Corrigendum: The characterization of an intestine-like genomic signature maintained during Barrett's-associated adenocarcinogenesis reveals an NR5A2-mediated promotion of cancer cell survival (Scientific Reports (2016) 6 (32638) DOI: 10.1038/srep32638);The characterization of an intestine-like genomic signature maintained during Barrett's-associated adenocarcinogenesis reveals an NR5A2-mediated promotion of cancer cell survival

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Duggan, Shane P ^a   Behan, Fiona M ^b   Kirca, Murat ^c   Zaheer, Abdul ^c   McGarrigle, Sarah A ^c   Reynolds, John V ^c   Vaz, Gisela M F ^b   Senge, Mathias O ^b   Kelleher, Dermot ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; NR5A2 PROTEIN, HUMAN; PROTEIN BCL X; TRANSCRIPTION FACTOR GATA 6;

ADENOCARCINOMA; APOPTOSIS; BARRETT ESOPHAGUS; CELL SURVIVAL; ESOPHAGUS TUMOR; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENE SILENCING; GENETICS; HUMAN; HUMAN GENOME; INTESTINE; METABOLISM; PATHOLOGY; REPRODUCIBILITY; STOMACH ACID; TUMOR CELL LINE;

ADENOCARCINOMA; APOPTOSIS; BARRETT ESOPHAGUS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; ESOPHAGEAL NEOPLASMS; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; GATA6 TRANSCRIPTION FACTOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENE SILENCING; GENOME, HUMAN; HUMANS; INTESTINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REPRODUCIBILITY OF RESULTS;

EID: 84986269486     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep35330     Document Type: Erratum

References (69)

1. Jung, K. W. et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. The American Journal of Gastroenterology 106, 1447, doi: 10. 1038/ajg. 2011. 130 (2011).
2. El-Serag, H. B., Sweet, S., Winchester, C. C. & Dent, J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 63, 871-880, doi: 10. 1136/gutjnl-2012-304269 (2013).
3. von Holzen, U. & Enders, G. H. A surprise cell of origin for Barrett's esophagus. Cancer Biology & Therapy 13, 588-591, doi: 10. 4161/cbt. 20088 (2012).
4. Fitzgerald, R. C. et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 63, 7-42, doi: 10. 1136/gutjnl-2013-305372 (2013).
5. Cook, M. B. et al. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON). Plos ONE 9, e103508, doi: 10. 1371/journal. pone. 0103508 (2014).
6. Krishnamoorthi, R. et al. Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. Gastrointestinal endoscopy, doi: 10. 1016/j. gie. 2015. 12. 036 (2016).
7. de Jonge, P. J. F. et al. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 59, 1030-1036, doi: 10. 1136/gut. 2009. 176701 (2010).
8. Sikkema, M., de Jonge, P. J. F., Steyerberg, E. W. & Kuipers, E. J. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 8, doi: 10. 1016/j. cgh. 2009. 10. 010 (2009).
9. Bhat, S. et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. JNCI Journal of the National Cancer Institute 103, 1049-1057, doi: 10. 1093/jnci/djr203 (2011).
10. Nicholson, A. M. et al. Barrett's metaplasia glands are clonal, contain multiple stem cells and share a common squamous progenitor. Gut 61, 1380-1389, doi: 10. 1136/gutjnl-2011-301174 (2011).
11. Singh, S., Garg, S. K., Singh, P. P., Iyer, P. G. & El-Serag, H. B. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut 63, 1229-1237, doi: 10. 1136/gutjnl-2013-305997 (2013).
12. Wang, X. et al. Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell 145, 1023-1035, doi: 10. 1016/j. cell. 2011. 05. 026 (2011).
13. Barros, R. et al. Key elements of the BMP/SMAD pathway co-localize with CDX2 in intestinal metaplasia and regulate CDX2 expression in human gastric cell lines. The Journal of Pathology 215, 411-420, doi: 10. 1002/path. 2369 (2008).
14. Kong, J., Crissey, M. A., Funakoshi, S., Kreindler, J. L. & Lynch, J. P. Ectopic Cdx2 expression in murine esophagus models an intermediate stage in the emergence of Barrett's esophagus. Plos ONE 6, e18280, doi: 10. 1371/journal. pone. 0018280 (2011).
15. Mari, L. et al. A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia. Cell reports 7, 1197-1210, doi: 10. 1016/j. celrep. 2014. 03. 074 (2014).
16. Hwang, J. T. K. & Kelly, G. M. GATA6 and FOXA2 regulate Wnt6 expression during extraembryonic endoderm formation. Stem Cells and Development 21, 3220-3232, doi: 10. 1089/scd. 2011. 0492 (2012).
17. Wang, D. H. et al. Hedgehog signaling regulates FOXA2 in esophageal embryogenesis and Barrett's metaplasia. Journal of Clinical Investigation 124, 3767-3780, doi: 10. 1172/JCI66603 (2014).
18. Watts, J. A. et al. Study of FoxA pioneer factor at silent genes reveals Rfx-repressed enhancer at Cdx2 and a potential indicator of esophageal adenocarcinoma development. Plos Genet 7, e1002277, doi: 10. 1371/journal. pgen. 1002277 (2011).
19. Wong, N. A. C. S. et al. CDX1 is an important molecular mediator of Barrett's metaplasia. Proceedings of the National Academy of Sciences 102, 7565-7570, doi: 10. 1073/pnas. 0502031102 (2005).
20. Kazumori, H., Ishihara, S. & Kinoshita, Y. Roles of caudal-related homeobox gene Cdx1 in oesophageal epithelial cells in Barrett's epithelium development. Gut 58, 620-628, doi: 10. 1136/gut. 2008. 152975 (2009).
21. Xie, Y. et al. Overexpression of Cdx2 inhibits progression of gastric cancer in vitro. International Journal of Oncology 36, 509-516 (2010).
22. Watari, J. et al. Differences in genetic instability and cellular phenotype among Barrett's, cardiac, gastric intestinal metaplasia in a Japanese population with Helicobacter pylori. Histopathology 55, 261-269, doi: 10. 1111/j. 1365-2559. 2009. 03370. x (2009).
23. Bandla, S. et al. Comparison of cancer-associated genetic abnormalities in columnar-lined esophagus tissues with and without goblet cells. Annals of Surgery 260, 72-80, doi: 10. 1097/SLA. 0000000000000424 (2014).
24. Salemme, M. et al. Intestinal metaplasia in Barrett's oesophagus: An essential factor to predict the risk of dysplasia and cancer development. Dig Liver Dis, doi: 10. 1016/j. dld. 2015. 10. 021 (2015).
25. Chandrasoma, P. et al. Columnar-lined esophagus without intestinal metaplasia has no proven risk of adenocarcinoma. The American Journal of Surgical Pathology 36, 1-7, doi: 10. 1097/PAS. 0b013e31822a5a2c (2011).
26. Lind, A. et al. The immune cell composition in Barrett's metaplastic tissue resembles that in normal duodenal tissue. Plos ONE 7, e33899, doi: 10. 1371/journal. pone. 0033899 (2012).
27. Arul, G. S. et al. Mucin gene expression in Barrett's oesophagus: an in situ hybridisation and immunohistochemical study. Gut 47, 753-761, doi: 10. 1136/gut. 47. 6. 753 (2000).
28. Corfield, A. P. et al. Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease. Gut 47, 589-594, doi: 10. 1136/gut. 47. 4. 589 (2000).
29. Sawhney, R. A. et al. Morphological characterization of the squamocolumnar junction of the esophagus in patients with and without Barrett's epithelium. Digestive diseases and sciences 41, 1088-1098 (1996).
30. Fléjou, J.-F. Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut 54 Suppl 1, i6-12, doi: 10. 1136/gut. 2004. 041525 (2005).
31. Kimchi, E. T. et al. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer research 65, 3146-3154, doi: 10. 1158/0008-5472. CAN-04-2490 (2005).
32. Ostrowski, J. et al. Molecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomics. Journal of Molecular Medicine 85, 733-743, doi: 10. 1007/s00109-007-0176-3 (2007).
33. Wang, Q., Ma, C. & Kemmner, W. Wdr66 is a novel marker for risk stratification and involved in epithelial-mesenchymal transition of esophageal squamous cell carcinoma. BMC cancer 13, 137, doi: 10. 1186/1471-2407-13-137 (2013).
34. Silvers, A. L. et al. Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity. Clinical Cancer Research 16, 2009-2021, doi: 10. 1158/1078-0432. CCR-09-2801 (2010).
35. Dalerba, P. et al. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med 374, 211-222, doi: 10. 1056/NEJMoa1506597 (2016).
36. Abu-Remaileh, M. et al. Chronic inflammation induces a novel epigenetic program that is conserved in intestinal adenomas and in colorectal cancer. Cancer Res 75, 2120-2130, doi: 10. 1158/0008-5472. CAN-14-3295 (2015).
37. Gharahkhani, P. et al. Chronic gastroesophageal reflux disease shares genetic background with esophageal adenocarcinoma and Barrett's esophagus. Hum Mol Genet, doi: 10. 1093/hmg/ddv512 (2015).
38. Beuling, E. et al. GATA6 is required for proliferation, migration, secretory cell maturation, gene expression in the mature mouse colon. Molecular and Cellular Biology 32, 3392-3402, doi: 10. 1128/MCB. 00070-12 (2012).
39. Lin, L. et al. Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma. Proceedings of the National Academy of Sciences 109, 4251-4256, doi: 10. 1073/pnas. 1011989109 (2012).
40. Krause, L. et al. Identification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinoma. Carcinogenesis 37, 356-365, doi: 10. 1093/carcin/bgw018 (2016).
41. Fernandez-Marcos, P. J., Auwerx, J. & Schoonjans, K. Emerging actions of the nuclear receptor LRH-1 in the gut. Biochimica et biophysica acta 1812, 947-955, doi: 10. 1016/j. bbadis. 2010. 12. 010 (2010).
42. Heng, J.-C. D. et al. The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells. Cell stem cell 6, 167-174, doi: 10. 1016/j. stem. 2009. 12. 009 (2010).
43. Out, C. et al. Liver receptor homolog-1 is critical for adequate up-regulation of Cyp7a1 gene transcription and bile salt synthesis during bile salt sequestration. Hepatology 53, 2075-2085, doi: 10. 1002/hep. 24286 (2011).
44. Atanasov, A. G. et al. Cell cycle-dependent regulation of extra-adrenal glucocorticoid synthesis in murine intestinal epithelial cells. The FASEB Journal 22, 4117-4125, doi: 10. 1096/fj. 08-114157 (2008).
45. Whissell, G. et al. The transcription factor GATA6 enables self-renewal of colon adenoma stem cells by repressing BMP gene expression. Nature Cell Biology 16, 695-707, doi: 10. 1038/ncb2992 (2014).
46. Kestens, C., Siersema, P. D., Offerhaus, G. J. & van Baal, J. W. BMP4 Signaling Is Able to Induce an Epithelial-Mesenchymal Transition-Like Phenotype in Barrett's Esophagus and Esophageal Adenocarcinoma through Induction of SNAIL2. Plos One 11, e0155754, doi: 10. 1371/journal. pone. 0155754 (2016).
47. Charong, N., Patmasiriwat, P. & Zenklusen, J. C. Localization and characterization of ST7 in cancer. Journal of Cancer Research and Clinical Oncology 137, 89-97, doi: 10. 1007/s00432-010-0863-2 (2010).
48. Hooi, C.-F. et al. ST7-mediated suppression of tumorigenicity of prostate cancer cells is characterized by remodeling of the extracellular matrix. Oncogene 25, 3924-3933, doi: 10. 1038/sj. onc. 1209418 (2006).
49. Shan, Z. et al. Overexpression of oxidored-nitro domain containing protein 1 induces growth inhibition and apoptosis in human prostate cancer PC3 cells. Oncology Reports 32, 1939-1946, doi: 10. 3892/or. 2014. 3407 (2014).
50. Cook, M. B. et al. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON). Plos One 9, e103508, doi: 10. 1371/journal. pone. 0103508 (2014).
51. Dai, J. Y. et al. A newly identified susceptibility locus near FOXP1 modifies the association of gastroesophageal reflux with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 24, 1739-1747, doi: 10. 1158/1055-9965. EPI-15-0507 (2015).
52. Gharahkhani, P. et al. Chronic gastroesophageal reflux disease shares genetic background with esophageal adenocarcinoma and Barrett's esophagus. Hum Mol Genet 25, 828-835, doi: 10. 1093/hmg/ddv512 (2016).
53. Levine, D. M. et al. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet 45, 1487-1493, doi: 10. 1038/ng. 2796 (2013).
54. Su, Z. et al. Common variants at the MHC locus and at chromosome 16q24. 1 predispose to Barrett's esophagus. Nature Genetics 44, 1131-1136, doi: 10. 1038/ng. 2408 (2012).
55. Lin, Y., Sohn, C. H., Dalal, C. K., Cai, L. & Elowitz, M. B. Combinatorial gene regulation by modulation of relative pulse timing. Nature 527, 54-58, doi: 10. 1038/nature15710 (2015).
56. Sailaja, B. S., Cohen-Carmon, D., Zimmerman, G., Soreq, H. & Meshorer, E. Stress-induced epigenetic transcriptional memory of acetylcholinesterase by HDAC4. Proc Natl Acad Sci USA 109, E3687-E3695, doi: 10. 1073/pnas. 1209990110 (2012).
57. Botrugno, O. A. et al. Synergy between LRH-1 and beta-catenin induces G1 cyclin-mediated cell proliferation. Molecular cell 15, 499-509, doi: 10. 1016/j. molcel. 2004. 07. 009 (2004).
58. Oosterveer, M. H. et al. LRH-1-dependent glucose sensing determines intermediary metabolism in liver. J Clin Invest 122, 2817-2826, doi: 10. 1172/JCI62368 (2012).
59. Oosterveer, M. H. & Schoonjans, K. Hepatic glucose sensing and integrative pathways in the liver. Cell Mol Life Sci 71, 1453-1467, doi: 10. 1007/s00018-013-1505-z (2014).
60. Benod, C. et al. Nuclear receptor liver receptor homologue 1 (LRH-1) regulates pancreatic cancer cell growth and proliferation. Proc Natl Acad Sci USA 108, 16927-16931, doi: 10. 1073/pnas. 1112047108 (2011).
61. Bianco, S., Jangal, M., Garneau, D. & Gevry, N. LRH-1 controls proliferation in breast tumor cells by regulating CDKN1A gene expression. Oncogene 34, 4509-4518, doi: 10. 1038/onc. 2014. 382 (2015).
62. Kramer, H. B. et al. LRH-1 drives colon cancer cell growth by repressing the expression of the CDKN1A gene in a p53-dependent manner. Nucleic Acids Res 44, 582-594, doi: 10. 1093/nar/gkv948 (2016).
63. Wagner, R. T., Xu, X., Yi, F., Merrill, B. J. & Cooney, A. J. Canonical Wnt/beta-catenin regulation of liver receptor homolog-1 mediates pluripotency gene expression. Stem Cells 28, 1794-1804, doi: 10. 1002/stem. 502 (2010).
64. Kwei, K. A. et al. Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. PLoS Genet 4, e1000081, doi: 10. 1371/journal. pgen. 1000081 (2008).
65. Fayter, D., Corbett, M., Heirs, M., Fox, D. & Eastwood, A. A systematic review of photodynamic therapy in the treatment of precancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin. Health Technology Assessment 14, 1-288, doi: 10. 3310/hta14370 (2010).
66. Duggan, S. P. et al. An integrative genomic approach in oesophageal cells identifies TRB3 as a bile acid responsive gene, downregulated in Barrett's oesophagus, which regulates NF-kappaB activation and cytokine levels. Carcinogenesis 31, 936-945, doi: 10. 1093/carcin/bgq036 (2010).
67. Benod, C. et al. Structure-based discovery of antagonists of nuclear receptor LRH-1. Journal of Biological Chemistry 288, 19830-19844, doi: 10. 1074/jbc. M112. 411686 (2013).
68. Vaz, G. M., Paszko, E., Davies, A. M. & Senge, M. O. High content screening as high quality assay for biological evaluation of photosensitizers in vitro. Plos One 8, e70653, doi: 10. 1371/journal. pone. 0070653 (2013).
69. Chou, T. C., Motzer, R. J., Tong, Y. Z. & Bosl, G. J. Computerized quantitation of synergism and antagonism of taxol, topotecan, cisplatin against human teratocarcinoma cell-growth-A rational approach to clinical protocol design. JNCI Journal of the National Cancer Institute 86, 1517-1524, doi: 10. 1093/jnci/86. 20. 1517 (1994).